Stage IIIB Skin Melanoma Recruiting Phase 2 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0029534 (Stage IIIB Skin Melanoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03719131Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab TherapyTreatment